MedTrace Logo

Comparison of Biologicals in Treatment of Severe Asthma

NCT04158050 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2023-12-04

Study results available
· View outcomes & findings →

Summary

This is a retrospective clinical study on adult patients (18 years or more) with biological therapy for severe asthma at the Helsinki University Central Hospital (HUCH). This is a real-life study with a broader patient population than in a randomized controlled trial. Omalizumab has been used for treatment of asthma in HUCH since January 2009, anti-IL5 therapies starting with mepolizumab since April 2016.

Conditions

Interventions

DRUG

IL5 Antagonist or anti-IL5R-antibody or Omalizumab

mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma

Sponsors & Collaborators

  • Ida Montini Foundation

    collaborator OTHER

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Paula Kauppi, MD, PhD · Helsinki University Central Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-10-31
Completion
2020-10-31
FDA Drug
Yes

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04158050 on ClinicalTrials.gov